Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 4, 2008, Pages 526-528

  Tenore, Simone ^a   Ferreira, Paolo A ^a   Diaz, Ricardo Sobhie ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; LOPINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAZIL; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; GENETIC PREDISPOSITION; GENOTYPE; HEALTH CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MULTIDRUG RESISTANCE; NAUSEA; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS STRAIN;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; CARBAMATES; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; SAQUINAVIR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 40549118153     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815b0d6f     Document Type: Letter

References (14)

1. Medeiros R, Diaz RS, Filho AC. Estimating the length of the first antiretroviral therapy regiment durability in Sao Paulo, Brazil. Braz J Infect Dis. 2002;6:298-304.
2. Sucupira MC, Souza IE, Costa LJ, et al. Antiretroviral treatment failure and HIV-1 genotypic resistance in Sao Paulo, Brazil. Antivir Ther. 2001;6:263-264.
3. Ananworanich J, Hirschel B, Sirivichayakul S, et al. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir Ther. 2006;11:631-635.
4. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir/ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482.
5. Smith GH, Boulassel MR, Klien M, et al. Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. HIV Clin Trials. 2005;6:63-72.
6. Raguin G, Chene G, Morand-Joubert L, et al. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther. 2004;9:615-625.
7. Taburet AM, Raguin G, Le Tiec C, et al. Interactions between amprenavir and the lopinavir/ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2004;75:310-323.
8. Deeks SG, Hoh R, Neilands TB, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis. 2005;192:1537-1544.
9. Duvivier CGJ, Assoumou L, Soulie C, et al. Lower rate of virological suppression in naive patients initiating HAART with NRTI-sparing regimen compared to standard NRTI-containing regimen: results from the Hippocampe - ANRS 121 trial [abstract]. Presented at: European AIDS Conference; 2005; Dublin. Abstract PS1/3.
10. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005;40:280-287.
11. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS. 2003;17:1339-1349.
12. Corbett AH, Eron JJ, Fiscus SA, et al. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr. 2004;36:921-928.
13. Elzi L, Hirsch HH, Battegay M. Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study. AIDS. 2006;20:129-131.
14. Ribera E, Azuaje C, Lopez RM, et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS. 2006;20:1131-1139.